

SPARC/Sec/SE/2019-20/044

9th December 2019

To

National Stock Exchange of India Ltd.

Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited

P J Towers,
Dalal street,
Mumbai - 400001

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Sub: Update on Taclantis ®

Dear Sir/Madam,

pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 and further to our letter No. SPARC/Sec/SE/2019-20/027 dated 20th August 2019 on the subject, we inform you that, Abraxis Biosciences LLC has dismissed the patent infringement complaint filed against SPARC regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension).

we enclose herewith the Update on the above-mentioned subject being released by the Company, which is self-explanatory.

You are requested to kindly take the same on your record & disseminate the information through your website.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**



For Debashis Dey
Company Secretary



Encls: A/a.



FOR IMMEDIATE RELEASE

SPARC Provides Update on Paclitaxel Injection Concentrate for Suspension (PICS) Litigation

Abraxis Bioscience LLC. dismissed complaint against SPARC

MUMBAI – December 09, 2019, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that Abraxis Bioscience LLC. has dismissed the patent infringement complaint filed against SPARC regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension).

"We are very pleased that Abraxis Bioscience LLC. has withdrawn its infringement claims paving the way for a successful launch as and when we receive necessary regulatory approvals," said Anil Raghavan, CEO of SPARC.

SPARC will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.

About PICS (Paclitaxel Injection Concentrate for Suspension):

PICS (Paclitaxel Injection Concentrate for Suspension) is a Cremophor[®] and Albumin-free formulation of Paclitaxel. PICS seeks the same indications as Abraxane[®]. Since it is Cremophor[®]-free, it can be diluted in either a PVC or non-PVC sterile infusion bag with an appropriate volume of 5% w/v Dextrose injection. Premedication to prevent hypersensitivity is generally not needed prior to administration of PICS. A New Drug Application for PICS is currently under review by the USFDA.

About SPARC (CIN: L73100GJ2006PLC047837):

Sun Pharma Advanced Research Company Ltd. ('SPARC') is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life.

Disclaimer:

Statements in this document describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

Media Contacts:

Jaydeep Issrani
Tel +91 22 66455645, Extn: 5787
Tel Direct +91 22 6645 5787
Mobile +91-9820216916
E mail jaydeep.issrani@sparcmail.com

®, TM - All brand names and trademarks are the property of respective owners.

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life

Registered Office : SPARC, Akota Road, Akota, Vadodara - 390 020, Gujarat, India.